Hematology/Oncology

Top Story

Timing, patterns of relapse predict survival after HSCT for multiple myeloma

Timing, patterns of relapse predict survival after HSCT for multiple myeloma
February 19, 2020
Meeting News

Higher total body irradiation dose fails to improve transplant outcomes in non-Hodgkin lymphoma

February 19, 2020
ORLANDO — Higher total body irradiation dose appeared associated with significantly higher risk for nonrelapse mortality and overall mortality among patients with…
In the Journals

CAR-T confers long-term quality-of-life improvement among patients with advanced lymphoma

February 19, 2020
Patients with relapsed or refractory diffuse large B-cell lymphoma experienced clinically meaningful improvements in long-term quality-of-life measurements after…
FDA News

FDA grants breakthrough therapy designation to Padcev regimen for advanced bladder cancer

February 19, 2020
The FDA granted breakthrough therapy designation to enfortumab vedotin-ejfv in combination with pembrolizumab for the treatment of patients with unresectable locally…
FDA News

FDA grants priority review to Tecentriq for first-line treatment of advanced non-small cell lung cancer

February 19, 2020
The FDA granted priority review to atezolizumab monotherapy as first-line treatment for patients with advanced nonsquamous or squamous non-small cell lung cancer without…
More Headlines »
Current Issues
View the Current Issue
HemOnc Today Cell Therapy Next